Trans Narva and Paide Share Points in Meistriliiga Draw
Trans Narva held on for a 1-1 draw against Paide in the twenty-third round of the Meistriliiga on Saturday. T. Berardozzi opened the scoring in the fourth minute before Andrade levelled for the visitors in the fifty-fifth. To be fair, the result reflected a game where one side controlled territory but the other held firm when it mattered.
Paide dominated possession at sixty-three percent and registered eighty-eight attacks compared to Narva's fifty-five. The hosts managed five shots on target against four for the visitors, but chances went begging for both sides. And here's the thing — you can dominate possession and still not find a way back into a match when the opposition keeps their heads.
Berardozzi's early goal came from a quick start that caught Paide slightly off-guard. Andrade's equaliser in the fifty-fifth minute shifted momentum, though neither side could break through. The yellow cards came steadily — Cabral and Berardozzi first, then Awusi, Ojamaa and Zuravljov — suggesting a match that grew increasingly physical as the second half progressed.
Substitutions began in the forty-sixth minute with three changes for Narva, while Paide brought on Elysee in the fifty-second. The pattern continued with Filatov and Luts for Narva in the sixty-seventh and seventieth minutes, and a trio of changes for the hosts in the eighty-second. Hoim came on late for Paide in the eighty-ninth minute.
Narva sit tenth with twenty-five points from twenty-five games, while Paide occupy fourth place on forty-two points after twenty-four matches. The draw extended Narva's recent form, coming after a heavy 8-0 victory over Company Mariamaa. Paide's result followed two disappointing defeats against Rapid Wien.
The statistics tell a familiar story — more attacks, more possession, fewer goals. Paide registered eight shots off target and only four on target, while Narva managed six off target and five on target. By then, the match had settled into a pattern where control meant little without clinical finishing.